The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The newly certified kits are designed for early detection and large-scale screening programs
Subscribe To Our Newsletter & Stay Updated